Roche's lung cancer drug wins US approval
Swiss drugmaker Roche Holding AG's new immunotherapy, Tecentriq, won approval on Tuesday from U.S. health regulators as a second-line lung cancer treatment, a decision seen likely to erode Bristol-Myers Squibb's position in this hotly contested market.
The U.S. Food and Drug Administration approved Tecentriq to be used in non-small cell lung cancer patients previously treated with chemotherapy, regardless of whether their tumors express a protein called PD-L1. People with high PD-L1 levels are generally more receptive to immunotherapy.
In study results released this month, patients getting... read more